Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

nd trade secret protection, for any reason, could allow other companies to make competing products and reduce the Group's product sales.

The Group has filed applications to register various trademarks for use in connection with its products in various countries including the US and countries in Europe and Latin America and intends to trademark new product names as new products are developed. In addition, with respect to certain products, the Group relies on the trademarks of third parties. These trademarks may not afford adequate protection or the Group or the third parties may not have the financial resources to enforce any rights under any of these trademarks. The Group's inability or the inability of these third parties to protect their trademarks because of successful third party claims to those trademarks could allow others to use the Group's trademarks and dilute their value.

If a marketed product fails to work effectively or causes adverse side effects, this could result in damage to the Group's reputation, the withdrawal of the product and legal action against the Group

Unanticipated side effects or unfavorable publicity concerning any of the Group's products, or those of its competitors, could have an adverse effect on the Group's ability to obtain or maintain regulatory approvals or successfully market its products. The testing, manufacturing, marketing and sales of pharmaceutical products entails a risk of product liability claims, product recalls, litigation and associated adverse publicity. The cost of defending against such claims is expensive even when the claims are not merited. A successful product liability claim against the Group could require the Group to pay a substantial monetary award. If, in the absence of adequate insurance coverage, the Group does not have sufficient financial resources to satisfy a liability resulting from such a claim or to fund the legal defense of such a
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22 de enero de 2015  El Dr. Paul ... llamada a nominaciones para 2015. Este prestigioso premio reconoce ... tiene el potencial para hacer, contribuciones destacadas para la ... hasta el 15 de marzo de 2015 a través ...
(Date:1/22/2015)... 22, 2015   GenoSpace , a precision medicine software company ... the broad use of genomic, imaging and other biomedical data ... Michelle Munson , CEO of Aspera, an IBM Company, ... - http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased ...
(Date:12/24/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ) ... ) has submitted a pre-market approval application to the ... of Medtronic,s SynchroMed ® II implantable drug infusion ... United Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously ...
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... for cells and tissues  ("BioLife" or the "Company"), today ... Stockholders on May 4, 2015 (the "Annual Meeting"). ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... 10 Essilor,of America, Essilor International,s US subsidiary, ... States with the acquisition,of Interstate Optical Co., one ... laboratories in Mansfield, Ohio and,Indianapolis, Indiana serve eye ... sales of US$26 million and 210 employees., ...
... 9 Hagens Berman Sobol Shapiro LLP,( ... business practices of CellCyte (OTC Bulletin Board: ... The investigation comes after CellCyte,s shares plunged ... in CellCyte CEO Gary,Reys, educational and professional ...
... Omeros Corporation announced today that,it has filed a ... the proposed initial public offering of shares of,its common ... sold in the offering,will be offered by Omeros. Deutsche ... manager. Pacific Growth Equities, LLC will be acting,as the ...
Cached Biology Technology:Hagens Berman Sobol Shapiro Investigating CellCyte 2Omeros Corporation Files Registration Statement for Proposed Initial Public Offering 2
(Date:1/22/2015)... , Jan. 13, 2015 Technology Showcase, Hall E ... identity authentication solutions, today announced it will showcase its EyeLock ... developed by the Department of Energy,s Oak Ridge National ... Auto Show . EyeLock,s iris identity authentication technology is being ...
(Date:1/22/2015)... , Jan. 16, 2015  A man-made form of insulin ... other mental capabilities in adults with mild cognitive impairment ... led by researchers at Wake Forest Baptist Medical Center. ... with amnesic mild cognitive impairment (MCI) or mild to ...
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... including technology and tech stocks, releases video from the CES ... and security consultant Apollo Robbins . Apollo ... the Wocket™ biometric smart wallet, a product of NXT-ID, Inc. ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... heredity is revealing, and two scientists who,ve studied the ... what,s most revealing to them is how fast both ... research assistant professor of biological sciences at the University ... and conservation biologist at the Chicago Zoological Society, compared ...
... 19 October 2007: Scientists have found that a large ... pre-disposition to the disease. The disease is the most ... common cause of admission to hospital in the first year ... 1,000 babies are admitted to hospital for bronchiolitis - needing ...
... to track one,s DNA to a specific country, region ... But while the popularity of genetic ancestry testing is ... is flawed and could spawn unwelcome societal consequences, according ... of California, Berkeley. "Because race has such profound ...
Cached Biology News:Mice roar message: genetic change happens fast 2Scientists find predisposition to bronchiolitis in some babies 2Genetic ancestral testing cannot deliver on its promise, study warns 2Genetic ancestral testing cannot deliver on its promise, study warns 3Genetic ancestral testing cannot deliver on its promise, study warns 4
... Imaging System, Professional Package Superior Protein ... Range: The ProXPRESS 2D Proteomic Imaging System ... for both proteomic and general life science ... enabling the use of all dyes in ...
... spatulas have been designed to save time ... those interested in eliminating the recycling and ... is individually packaged, RNase/DNase free, non-pyrogenic and ... new product number, created to easily match ...
... three-way universal digital valve, just 8 mm in ... functional features in a single glass-reinforced, PBT (Polybutylene ... 8mm in width. , Meets a range of ... psi. , Satisfies a 0.016 sccm leakage specification ...
... versatile system that simultaneously harvests and washes ... into a solid filter supports for analysis ... counter. The FilterMate is ideal for the ... cell proliferation, receptor binding, nucleic acid degradation, ...
Biology Products: